• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

环氧化酶2在巴雷特食管和腺癌中的表达:胆汁盐和酸暴露的体外诱导作用

Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure.

作者信息

Shirvani V N, Ouatu-Lascar R, Kaur B S, Omary M B, Triadafilopoulos G

机构信息

Gastroenterology Section, Palo Alto Veterans Affairs Health Care System, Palo Alto, California 94304, USA.

出版信息

Gastroenterology. 2000 Mar;118(3):487-96. doi: 10.1016/s0016-5085(00)70254-x.

DOI:10.1016/s0016-5085(00)70254-x
PMID:10702199
Abstract

BACKGROUND & AIMS: Barrett's esophagus (BE) results from chronic, severe gastroesophageal reflux and predisposes to esophageal adenocarcinoma. Cyclooxygenase (COX)-2 is involved in chronic inflammation and epithelial cell growth. We investigated COX-2 expression in BE and esophageal adenocarcinoma to explore a potential relation between COX-2 expression and metaplasia or carcinogenesis.

METHODS

Endoscopic mucosal biopsy specimens of Barrett's intestinal metaplasia (n = 30), Barrett's dysplasia (n = 11), and esophageal adenocarcinoma (n = 5) were compared with normal esophagus (n = 46) and duodenum (n = 46) and analyzed by Western blotting and immunohistochemistry.

RESULTS

Immunoblots revealed constitutive expression of COX-2 in normal esophagus and duodenum. COX-2 protein expression was significantly higher in patients with Barrett's metaplasia, dysplasia, and adenocarcinoma compared with normal squamous esophageal or columnar duodenal epithelia and was heterogenous in different regions of the BE surface. Immunohistochemistry revealed prominent staining in the glands of BE, dysplasia, and adenocarcinoma and faint staining in the basal layers of squamous esophagus and the surface of the duodenum. In response to pulses of acid or bile salts in an ex vivo organ culture system, COX-2 expression increased significantly in BE tissues, and this effect was attenuated by the selective COX-2 inhibitor NS-398.

CONCLUSIONS

The results show COX-2 expression in normal esophagus, which increases significantly in BE and esophageal adenocarcinoma. COX-2 is regulated ex vivo by exposure to acid or bile salts.

摘要

背景与目的

巴雷特食管(BE)由慢性严重胃食管反流引起,易患食管腺癌。环氧化酶(COX)-2参与慢性炎症和上皮细胞生长。我们研究了COX-2在BE和食管腺癌中的表达,以探讨COX-2表达与化生或癌变之间的潜在关系。

方法

将巴雷特肠化生(n = 30)、巴雷特异型增生(n = 11)和食管腺癌(n = 5)的内镜黏膜活检标本与正常食管(n = 46)和十二指肠(n = 46)进行比较,并通过蛋白质免疫印迹法和免疫组织化学分析。

结果

蛋白质免疫印迹显示COX-2在正常食管和十二指肠中组成性表达。与正常鳞状食管或柱状十二指肠上皮相比,巴雷特化生、异型增生和腺癌患者的COX-2蛋白表达显著更高,且在BE表面的不同区域存在异质性。免疫组织化学显示,BE、异型增生和腺癌的腺体中染色明显,鳞状食管基底层和十二指肠表面染色较弱。在体外器官培养系统中,对酸或胆盐脉冲的反应中,BE组织中COX-2表达显著增加,且这种效应被选择性COX-2抑制剂NS-398减弱。

结论

结果显示COX-2在正常食管中有表达,在BE和食管腺癌中显著增加。COX-2在体外受酸或胆盐暴露的调节。

相似文献

1
Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure.环氧化酶2在巴雷特食管和腺癌中的表达:胆汁盐和酸暴露的体外诱导作用
Gastroenterology. 2000 Mar;118(3):487-96. doi: 10.1016/s0016-5085(00)70254-x.
2
The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study.选择性环氧化酶-2抑制对巴雷特食管上皮细胞的作用:一项体外研究。
J Natl Cancer Inst. 2002 Mar 20;94(6):422-9. doi: 10.1093/jnci/94.6.422.
3
Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.环氧化酶-2在巴雷特化生-发育异常-腺癌序列中的表达。
Am J Gastroenterol. 2001 Apr;96(4):990-6. doi: 10.1111/j.1572-0241.2001.03599.x.
4
Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma.环氧化酶-2在巴雷特食管及相关腺癌中频繁且早期表达。
Histopathology. 2003 May;42(5):457-65. doi: 10.1046/j.1365-2559.2003.01627.x.
5
Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids.十二指肠反流可诱导大鼠食管黏膜中环氧合酶-2的产生:胆汁酸参与其中的证据。
Gastroenterology. 2001 Dec;121(6):1391-9. doi: 10.1053/gast.2001.29781.
6
Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus.罗非昔布抑制环氧化酶2的表达和活性,并减少巴雷特食管中的细胞增殖。
Gastroenterology. 2002 Jul;123(1):60-7. doi: 10.1053/gast.2002.34244.
7
Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.巴雷特食管中脂肪酸合酶的表达:对癌变的影响。
J Clin Gastroenterol. 2011 Sep;45(8):665-72. doi: 10.1097/MCG.0b013e318207f240.
8
Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.胃泌素诱导的环氧化酶-2在巴雷特食管癌变中的表达
Clin Cancer Res. 2004 Jul 15;10(14):4784-92. doi: 10.1158/1078-0432.CCR-04-0015.
9
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.诱导型一氧化氮合酶和环氧化酶-2在巴雷特食管及其相关腺癌中的表达增加。
Cancer Res. 1998 Jul 15;58(14):2929-34.
10
COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer.环氧化酶-2抑制在食管炎、巴雷特食管和食管癌中的作用
Curr Pharm Des. 2003;9(27):2267-80. doi: 10.2174/1381612033454009.

引用本文的文献

1
A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database.一项基于美国食品药品监督管理局不良事件报告系统数据库的质子泵抑制剂与肿瘤不良事件关联的药物警戒研究。
Front Pharmacol. 2024 Dec 19;15:1524903. doi: 10.3389/fphar.2024.1524903. eCollection 2024.
2
Effectiveness of long-term low-dose aspirin in the prevention of gastric cancer after Helicobacter pylori eradication: study design and rationale of Ardabil gastric cancer randomized placebo-controlled prevention trial (AGCPT).长期低剂量阿司匹林在幽门螺杆菌根除后预防胃癌的效果:阿瓦士胃癌随机安慰剂对照预防试验(AGCPT)的研究设计和原理。
Trials. 2024 Sep 19;25(1):617. doi: 10.1186/s13063-024-08455-5.
3
Molecular Biology and Clinical Management of Esophageal Adenocarcinoma.食管腺癌的分子生物学与临床管理
Cancers (Basel). 2023 Nov 14;15(22):5410. doi: 10.3390/cancers15225410.
4
Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy.长期质子泵抑制剂治疗停药后胃和食管腺癌的风险。
J Gastroenterol. 2022 Dec;57(12):942-951. doi: 10.1007/s00535-022-01930-3. Epub 2022 Oct 18.
5
Risk of esophageal adenocarcinoma in patients with Barrett's esophagus using proton pump inhibitors: a systematic review with meta-analysis and sequential trial analysis.使用质子泵抑制剂的巴雷特食管患者患食管腺癌的风险:一项系统评价及荟萃分析与序贯试验分析
Transl Cancer Res. 2021 Apr;10(4):1620-1627. doi: 10.21037/tcr-20-3362.
6
Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma.内脏肥胖、代谢综合征与食管腺癌
Front Oncol. 2021 Mar 12;11:627270. doi: 10.3389/fonc.2021.627270. eCollection 2021.
7
Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway.丹参酮IIA和顺铂联合通过下调NF-κB/COX-2/VEGF通路抑制食管癌
Front Oncol. 2020 Sep 10;10:1756. doi: 10.3389/fonc.2020.01756. eCollection 2020.
8
Adenocarcinoma originating from long-segment Barrett's esophagus over 15 cm: a series of 3 cases.起源于超过15厘米长段巴雷特食管的腺癌:3例系列报道
Surg Case Rep. 2020 Sep 29;6(1):230. doi: 10.1186/s40792-020-00995-7.
9
Chemoprevention of esophageal adenocarcinoma.食管腺癌的化学预防
Gastroenterol Rep (Oxf). 2020 Jul 24;8(4):253-260. doi: 10.1093/gastro/goaa040. eCollection 2020 Aug.
10
Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development.靶向 COX1/2 驱动的血栓素 A2 通路抑制 Barrett 食管和食管腺癌的发展。
EBioMedicine. 2019 Nov;49:145-156. doi: 10.1016/j.ebiom.2019.10.038. Epub 2019 Nov 7.